Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2

Lung Cancer ◽  
2015 ◽  
Vol 89 (3) ◽  
pp. 274-279 ◽  
Author(s):  
Luciene Schluckebier ◽  
Osvaldo U. Garay ◽  
Mauro Zukin ◽  
Carlos G. Ferreira
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
And Performance

160 The impact of age and performance status on outcome of brain metastases in non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2012 ◽  
Vol 75 ◽  
pp. S52
Author(s):  
E. Larbi ◽  
G. Middleton ◽  
T. Partridge-James ◽  
S. Quirin ◽  
V. Hardacre ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
And Performance ◽  
The Impact

Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes

2020 ◽  
Vol 21 (5) ◽  
pp. e388-e404
Author(s):  
Rebekah Rittberg ◽  
Susan Green ◽  
Trevor Aquin ◽  
Oliver Bucher ◽  
Shantanu Banerji ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Cancer Outcomes ◽  
Small Cell Lung ◽  
And Performance
Sign in / Sign up

Export Citation Format

Share Document